Patient derived ex vivo tissue slice cultures demonstrate a profound DNA double-strand break repair defect in HPV-positive oropharyngeal head and neck cancer.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
03 2022
Historique:
received: 29 06 2021
revised: 11 01 2022
accepted: 16 01 2022
pubmed: 31 1 2022
medline: 8 4 2022
entrez: 30 1 2022
Statut: ppublish

Résumé

HPV-positive head and neck squamous cell carcinoma of the oropharynx (OPSCC) are more sensitive towards radiation than HPV-negative OPSCC. Two main theories exist regarding the underlying mechanism. Stronger lymphocyte infiltration points to an enhanced immunogenicity, whereas data from HPV-positive HNSCC cell lines suggest an enhanced cellular radiosensitivity based on a defect in DNA double-strand break (DSB) repair. The critical limitation of the latter theory is that the evidence was largely derived from a small number of established HPV-positive HNSCC cell lines. Fresh patient-derived OPSCC samples were cut in 400 µm sections and cultured on cell culture inserts. Slice cultures were irradiated, in part combined with ATM inhibition, and fixed and frozen after 2 and 24 h. DSBs were analyzed by quantification of 53BP1 foci in nuclei co-stained with the SCC marker p63 via immunofluorescence microscopy. Ex vivo OPSCC tumor slice cultures maintained stable oxygenation and proliferation characteristics for at least 3 days. Areas of p63-positivity in immunofluorescence microscopy matched histologically confirmed tumor cell areas in serial sections, indicating the suitability of p63 as a tumor cell marker. p63-positive nuclei in HPV-positive OPSCC tissues (n = 14) showed profoundly elevated numbers of residual radiation-induced DSBs as compared to those from HPV-negative OPSCC (n = 12) (3 Gy: on average 4.9 vs. 1.2 foci per nucleus; p < 0.0001). Within the HPV-positive subgroup, samples derived from patients with a smoking history of less than 10 pack years demonstrated higher residual DSBs as compared to those derived from patients with 10 or more pack years (3 Gy: on average 6.5 vs. 3.2 foci per nucleus; p = 0.0105). Additional ATM inhibition resulted in a substantial increase in residual foci in all 4 HPV-negative samples tested but strikingly only in 2 out of 11 HPV-positive samples. In summary, our data provide robust, cell line-independent experimental evidence for an intrinsic DSB repair deficiency in HPV-positive OPSCC, strongly suggesting a meaningful contribution to the enhanced clinical radiosensitivity. The reduced effectiveness of ATM inhibition indicates a defect in the ATM-orchestrated DNA damage response. Lower numbers of residual 53BP1 nuclear foci in the ex vivo assay may identify HPV-positive patients with effective DSB repair who should potentially be excluded from de-intensification approaches.

Sections du résumé

BACKGROUND
HPV-positive head and neck squamous cell carcinoma of the oropharynx (OPSCC) are more sensitive towards radiation than HPV-negative OPSCC. Two main theories exist regarding the underlying mechanism. Stronger lymphocyte infiltration points to an enhanced immunogenicity, whereas data from HPV-positive HNSCC cell lines suggest an enhanced cellular radiosensitivity based on a defect in DNA double-strand break (DSB) repair. The critical limitation of the latter theory is that the evidence was largely derived from a small number of established HPV-positive HNSCC cell lines.
METHODS AND MATERIALS
Fresh patient-derived OPSCC samples were cut in 400 µm sections and cultured on cell culture inserts. Slice cultures were irradiated, in part combined with ATM inhibition, and fixed and frozen after 2 and 24 h. DSBs were analyzed by quantification of 53BP1 foci in nuclei co-stained with the SCC marker p63 via immunofluorescence microscopy.
RESULTS
Ex vivo OPSCC tumor slice cultures maintained stable oxygenation and proliferation characteristics for at least 3 days. Areas of p63-positivity in immunofluorescence microscopy matched histologically confirmed tumor cell areas in serial sections, indicating the suitability of p63 as a tumor cell marker. p63-positive nuclei in HPV-positive OPSCC tissues (n = 14) showed profoundly elevated numbers of residual radiation-induced DSBs as compared to those from HPV-negative OPSCC (n = 12) (3 Gy: on average 4.9 vs. 1.2 foci per nucleus; p < 0.0001). Within the HPV-positive subgroup, samples derived from patients with a smoking history of less than 10 pack years demonstrated higher residual DSBs as compared to those derived from patients with 10 or more pack years (3 Gy: on average 6.5 vs. 3.2 foci per nucleus; p = 0.0105). Additional ATM inhibition resulted in a substantial increase in residual foci in all 4 HPV-negative samples tested but strikingly only in 2 out of 11 HPV-positive samples.
CONCLUSIONS
In summary, our data provide robust, cell line-independent experimental evidence for an intrinsic DSB repair deficiency in HPV-positive OPSCC, strongly suggesting a meaningful contribution to the enhanced clinical radiosensitivity. The reduced effectiveness of ATM inhibition indicates a defect in the ATM-orchestrated DNA damage response. Lower numbers of residual 53BP1 nuclear foci in the ex vivo assay may identify HPV-positive patients with effective DSB repair who should potentially be excluded from de-intensification approaches.

Identifiants

pubmed: 35093407
pii: S0167-8140(22)00022-6
doi: 10.1016/j.radonc.2022.01.017
pii:
doi:

Substances chimiques

DNA 9007-49-2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

138-146

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Henrike Barbara Zech (HB)

Department of Otorhinolaryngology, University Medical Center Hamburg Eppendorf, Germany; Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg Eppendorf, Germany.

Joanna Berger (J)

Department of Otorhinolaryngology, University Medical Center Hamburg Eppendorf, Germany.

Wael Yassin Mansour (WY)

Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg Eppendorf, Germany; Mildred-Scheel Cancer Career Center HaTriCS(4), University Medical Center Hamburg Eppendorf, Germany.

Lena Nordquist (L)

Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg Eppendorf, Germany.

Clara Marie von Bargen (CM)

Institute of Pathology, University Medical Center Hamburg Eppendorf, Germany.

Lara Bußmann (L)

Department of Otorhinolaryngology, University Medical Center Hamburg Eppendorf, Germany.

Agnes Oetting (A)

Department of Otorhinolaryngology, University Medical Center Hamburg Eppendorf, Germany; Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg Eppendorf, Germany.

Sabrina Christiansen (S)

Department of Otorhinolaryngology, University Medical Center Hamburg Eppendorf, Germany; Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg Eppendorf, Germany.

Nikolaus Möckelmann (N)

Department of Otorhinolaryngology, University Medical Center Hamburg Eppendorf, Germany; Department of Otorhinolaryngology, Marienkrankenhaus Hamburg, Germany.

Arne Böttcher (A)

Department of Otorhinolaryngology, University Medical Center Hamburg Eppendorf, Germany.

Chia-Jung Busch (CJ)

Department of Otorhinolaryngology, University Medical Center Hamburg Eppendorf, Germany; Department of Otorhinolaryngology, University Medical Center Greifswald, Germany.

Cordula Petersen (C)

Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg Eppendorf, Germany.

Christian Betz (C)

Department of Otorhinolaryngology, University Medical Center Hamburg Eppendorf, Germany.

Kai Rothkamm (K)

Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg Eppendorf, Germany.

Malte Kriegs (M)

Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg Eppendorf, Germany.

Sabrina Köcher (S)

Department of Otorhinolaryngology, University Medical Center Hamburg Eppendorf, Germany; Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg Eppendorf, Germany.

Thorsten Rieckmann (T)

Department of Otorhinolaryngology, University Medical Center Hamburg Eppendorf, Germany; Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg Eppendorf, Germany. Electronic address: t.rieckmann@uke.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH